Lee Hwa-Suk, Ka Sun-O, Lee Sang-Myeong, Lee Sang-Il, Park Jin-Woo, Park Byung-Hyun
Chonbuk National University, Jeonbuk, Republic of Korea.
Arthritis Rheum. 2013 Jul;65(7):1776-85. doi: 10.1002/art.37963.
Sirtuin 6 (SIRT-6) is an NAD(+) -dependent deacetylase and mono-ADP-ribosyltransferase. It is known to interfere with the NF-κB signaling pathway and thereby has an antiinflammatory function. Due to the central role of NF-κB in rheumatoid arthritis (RA) development, we undertook this study to test our hypothesis that SIRT-6 could have antiarthritic effects.
An adenovirus containing SIRT-6 complementary DNA (Ad-SIRT6) was used to deliver SIRT-6 to human RA fibroblast-like synoviocytes in vitro as well as to mice with collagen-induced arthritis (CIA) in vivo via bilateral intraarticular injections into the ankle joints.
In vitro experiments demonstrated that SIRT-6 overexpression suppressed NF-κB target gene expression induced by tumor necrosis factor α. SIRT-6 overexpression inhibited osteoclast differentiation induced by macrophage colony-stimulating factor and RANKL in bone marrow-derived macrophages. Mice with CIA had an increased incidence of disease and developed arthritis in the hind paws. In contrast, mice injected with Ad-SIRT6 showed attenuated severity of arthritis based on clinical scores, hind paw thickness, and radiographic and pathologic findings. Moreover, the injection of Ad-SIRT6 down-regulated local and systemic levels of proinflammatory cytokines. After induction of CIA, mice injected with Ad-SIRT6 showed significantly decreased arthritis severity, from the onset of clinical signs to the end of the study.
These results suggest that blocking the NF-κB pathway by SIRT-6 in rheumatoid joints reduces both the inflammatory response and tissue destruction. Therefore, the development of an immunoregulatory strategy based on SIRT-6 may have therapeutic potential for the treatment of RA.
沉默调节蛋白6(SIRT-6)是一种依赖烟酰胺腺嘌呤二核苷酸(NAD(+))的脱乙酰酶和单磷酸腺苷核糖基转移酶。已知它可干扰核因子κB(NF-κB)信号通路,从而具有抗炎功能。由于NF-κB在类风湿关节炎(RA)发病过程中起核心作用,我们进行了本研究以验证SIRT-6可能具有抗关节炎作用这一假设。
携带SIRT-6互补DNA的腺病毒(Ad-SIRT6)用于在体外将SIRT-6递送至人RA成纤维细胞样滑膜细胞,并通过双侧踝关节腔内注射在体内递送至胶原诱导性关节炎(CIA)小鼠。
体外实验表明,SIRT-6过表达抑制了肿瘤坏死因子α诱导的NF-κB靶基因表达。SIRT-6过表达抑制了骨髓来源巨噬细胞中巨噬细胞集落刺激因子和核因子κB受体活化因子配体(RANKL)诱导的破骨细胞分化。CIA小鼠疾病发病率增加且后爪出现关节炎。相比之下,注射Ad-SIRT6的小鼠根据临床评分、后爪厚度以及影像学和病理学结果显示关节炎严重程度减轻。此外,注射Ad-SIRT6下调了促炎细胞因子的局部和全身水平。诱导CIA后,从临床症状出现到研究结束,注射Ad-SIRT6的小鼠关节炎严重程度显著降低。
这些结果表明,类风湿关节中SIRT-6阻断NF-κB通路可减轻炎症反应和组织破坏。因此,基于SIRT-6的免疫调节策略的开发可能对RA治疗具有治疗潜力。